Big companies are catching on to the automation trend, so the market must be growing. Read More

Today, I am (1) closing out a bonus position I recommended earlier this year in Celldex Therapeutics (Nasdaq: CLDX); (2) increasing the buy limit on my latest pick Diebold Nixdorf (NYSE: DBD); and, (3) changing my rating on Ambarella (Nasdaq: AMBA) to ‘Hold’. I explain the rationale for these moves in… Read More

This highly priced stock is ripe for a bet that its share price will fall. Read More

Diebold is buying its way into global growth and new businesses. Read More

Fewer customers is this online marketer’s growth strategy in action. Read More

Innogration is key for putting firms on a track to change and success. Read More

I am raising the rating on Medidata Solutions (NSDQ: MDSO), the leading cloud based software platform for biotech research management to Buy from Hold.  I recommended the stock in March 2015 and so far it has delivered a 51% price increase.  But recent price behavior suggests that it’s poised for… Read More

After years of technical and production challenges, sales of Virtual Reality sets are finally becoming reality. Read More

As we noted in last week’s alert, Ekso Bionics (EKSO) announced last Tuesday that it would raise additional capital by issuing 3.75 million new shares of common stock at a price of $4.00 per share. On Friday, the company confirmed that it had successfully closed that offering, generating… Read More